Patents by Inventor Jeffrey D. Hermes

Jeffrey D. Hermes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?-lactamase inhibitors
    Patent number: 8487093
    Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are ?-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds can be employed with a ?-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy A. Blizzard, Helen Chen, Candido Gude, Jeffrey D. Hermes, Jason Imbriglio, Seongkon Kim, Jane Y. Wu, Christopher J. Mortko, Ian Mangion, Nelo Rivera, Rebecca T. Ruck, Michael Shevlin
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20110294777
    Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are ?-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds can be employed with a ?-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Application
    Filed: January 15, 2009
    Publication date: December 1, 2011
    Inventors: Timothy A. Blizzard, Helen Chen, Candido Gude, Jeffrey D. Hermes, Jason Imbriglio, Seongkon Kim, Jane Y. Wu, Sookhee Ha, Christopher J. Mortko, Ian Mangion, Nelo Rivera, Rebecca T. Ruck, Michael Shevlin
  • Reagents for assaying Bacillus anthracis lethal factor protease
    Patent number: 6955891
    Abstract: The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 18, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe
  • Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
    Patent number: 6689574
    Abstract: Provided is a method of identifying agonists and antagonists of nuclear receptors that comprises measuring agonist-dependent fluorescence resonance energy transfer (FRET) between a fluorescently labeled nuclear receptor or ligand binding domain and fluorescently labeled CREB-binding protein (CBP), p300, other nuclear co-activator, or binding portion thereof. The method is simple, rapid, and inexpensive. Nuclear receptors and nuclear receptor co-activators labeled with fluorescent reagents for use in the above-described method are also provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Richard T. Cummings, David E. Moller, Jeffrey D. Hermes, Gaochao Zhou
  • Reagents and methods for assaying Bacillus anthracis lethal factor protease
    Publication number: 20040019182
    Abstract: The present invention features a Bacillus anthracis lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for compounds affecting lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate to be suitable for use in a high throughput screen.
    Type: Application
    Filed: April 28, 2003
    Publication date: January 29, 2004
    Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe
  • Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
    Patent number: 5719296
    Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John J. Acton, III, Alan D. Adams, Jeffrey D. Hermes, A. Brian Jones, William Hugh Parsons, Peter J. Sinclair